Amicus Therapeutics, Inc. (NASDAQ:FOLD) Stake Decreased by BNP Paribas Arbitrage SA

BNP Paribas Arbitrage SA lessened its holdings in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 3.1% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 755,041 shares of the biopharmaceutical company’s stock after selling 24,282 shares during the period. BNP Paribas Arbitrage SA owned 0.28% of Amicus Therapeutics worth $7,279,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also added to or reduced their stakes in FOLD. First Trust Advisors LP bought a new stake in shares of Amicus Therapeutics during the first quarter valued at approximately $635,000. US Bancorp DE raised its holdings in shares of Amicus Therapeutics by 3,408.4% during the first quarter. US Bancorp DE now owns 11,227 shares of the biopharmaceutical company’s stock valued at $111,000 after buying an additional 10,907 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Amicus Therapeutics by 8.3% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 32,092 shares of the biopharmaceutical company’s stock valued at $317,000 after buying an additional 2,459 shares during the last quarter. Envestnet Asset Management Inc. raised its holdings in Amicus Therapeutics by 172.9% during the first quarter. Envestnet Asset Management Inc. now owns 92,768 shares of the biopharmaceutical company’s stock worth $917,000 after purchasing an additional 58,776 shares in the last quarter. Finally, Mitsubishi UFJ Kokusai Asset Management Co. Ltd. raised its holdings in Amicus Therapeutics by 53.3% during the first quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 16,622 shares of the biopharmaceutical company’s stock worth $164,000 after purchasing an additional 5,777 shares in the last quarter.

Several equities research analysts recently commented on FOLD shares. Chardan Capital reissued a “neutral” rating on shares of Amicus Therapeutics in a report on Thursday, July 1st. BTIG Research started coverage on Amicus Therapeutics in a report on Monday, July 19th. They set a “buy” rating and a $15.00 target price on the stock. Berenberg Bank started coverage on Amicus Therapeutics in a report on Thursday, July 1st. They set a “hold” rating and a $14.00 target price on the stock. Needham & Company LLC started coverage on Amicus Therapeutics in a report on Thursday, May 27th. They set a “hold” rating on the stock. Finally, SVB Leerink reaffirmed a “hold” rating on shares of Amicus Therapeutics in a report on Thursday, June 10th. Eight equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $19.42.

In other news, CEO John F. Crowley sold 37,000 shares of the business’s stock in a transaction on Thursday, August 5th. The shares were sold at an average price of $10.03, for a total transaction of $371,110.00. Following the transaction, the chief executive officer now directly owns 884,345 shares in the company, valued at approximately $8,869,980.35. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Samantha Prout sold 5,045 shares of the company’s stock in a transaction on Monday, August 23rd. The stock was sold at an average price of $11.00, for a total transaction of $55,495.00. Following the completion of the sale, the insider now owns 83,170 shares of the company’s stock, valued at $914,870. The disclosure for this sale can be found here. Over the last quarter, insiders have acquired 4,500 shares of company stock worth $45,435 and have sold 150,136 shares worth $1,574,867. Insiders own 2.10% of the company’s stock.

NASDAQ FOLD opened at $11.02 on Wednesday. Amicus Therapeutics, Inc. has a twelve month low of $8.60 and a twelve month high of $25.39. The company has a debt-to-equity ratio of 1.83, a quick ratio of 4.08 and a current ratio of 4.29. The stock has a market cap of $2.94 billion, a price-to-earnings ratio of -11.48 and a beta of 1.10. The firm’s 50 day moving average price is $10.36 and its two-hundred day moving average price is $9.99.

Amicus Therapeutics (NASDAQ:FOLD) last posted its quarterly earnings data on Wednesday, August 4th. The biopharmaceutical company reported ($0.19) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.03. Amicus Therapeutics had a negative net margin of 89.53% and a negative return on equity of 91.47%. The firm had revenue of $77.41 million for the quarter, compared to analysts’ expectations of $71.35 million. On average, research analysts forecast that Amicus Therapeutics, Inc. will post -0.79 EPS for the current fiscal year.

About Amicus Therapeutics

Amicus Therapeutics, Inc operates as a biotechnology company. The firm focuses on discovering, developing and delivering medicines for people living with metabolic diseases. Its product portfolio includes first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants, a novel, clinical-stage, treatment paradigm for Pompe disease and a rare disease gene therapy portfolio.

Read More: How to execute a trade ex-dividend strategy?

Institutional Ownership by Quarter for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.